Log in

NASDAQ:XNCRXencor Stock Price, Forecast & News

$31.83
+1.74 (+5.78 %)
(As of 08/3/2020 04:00 PM ET)
Add
Compare
Today's Range
$30.19
Now: $31.83▼
$31.98
50-Day Range
$28.43
MA: $31.96▼
$35.48
52-Week Range
$19.35
Now: $31.83▼
$46.33
Volume310,919 shs
Average Volume277,302 shs
Market Capitalization$1.81 billion
P/E RatioN/A
Dividend YieldN/A
Beta1.01
Xencor, Inc., a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and other protein therapeutics to treat severe and life threatening diseases with unmet medical needs. It develops its antibody product candidates to treat autoimmune and allergic diseases, cancer, and other conditions. The company's product candidates include XmAb5871, an immune inhibitor, which has been completed Phase II clinical trial for the treatment of autoimmune diseases; and XmAb7195, an immune inhibitor that has been completed Phase I clinical trial for the treatment of asthma and allergic diseases. Its product candidates also comprise XmAb14045, a bispecific oncology candidate, which is in Phase I clinical trial for the treatment of acute myeloid leukemia; XmAb13676 that is in Phase I clinical trial to treat B-cell malignancies; and XmAb18087, which is in Phase I clinical trial for neuroendocrine tumors and gastrointestinal stromal tumors. In addition, the company offers MOR208, an antibody drug that is in Phase III clinical trial to treat non-Hodgkin lymphomas, as well as in Phase II clinical trial for chronic lymphocytic leukemia; AMG424, a bispecific antibody that targets CD38 and CD3, which is in Phase I clinical trial for the treatment of various myeloma; and AMG50, a bispecific antibody that is in preclinical development stage to treat prostate cancer. Further, it is developing bispecific antibodies to treat various cancers, such as XmAb20717, XmAb22841, XmAb23104, and XmAb24306 which are in preclinical Phase. The company has collaboration and license agreement with Novartis Institutes for BioMedical Research, Inc.; MorphoSys Ag; Amgen Inc.; and Catalent Pharma Solutions LLC. Xencor, Inc. was founded in 1997 and is headquartered in Monrovia, California.
Read More
Xencor logo

Beat the Market (BTM) Rank™

Analyst Opinion: 3.2Community Rank: 3.0Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank™

1.56 out of 5 stars


Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:XNCR
Previous Symbol
CUSIPN/A
CIK1326732
Webwww.xencor.com
Phone626-305-5900

Debt

Debt-to-Equity Ratio0.01
Current Ratio8.92
Quick Ratio8.92

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual Sales$156.70 million
Price / Sales11.58
Cash Flow$0.54 per share
Price / Cash Flow58.44
Book Value$10.46 per share
Price / Book3.04

Profitability

EPS (Most Recent Fiscal Year)$0.46
Net Income$26.88 million
Net Margins-79.39%
Return on Equity-10.40%
Return on Assets-9.24%

Miscellaneous

Employees156
Outstanding Shares57,010,000
Market Cap$1.81 billion
Next Earnings Date8/4/2020 (Confirmed)
OptionableOptionable
$31.83
+1.74 (+5.78 %)
(As of 08/3/2020 04:00 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive XNCR News and Ratings via Email

Sign-up to receive the latest news and ratings for XNCR and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Xencor (NASDAQ:XNCR) Frequently Asked Questions

How has Xencor's stock been impacted by COVID-19 (Coronavirus)?

Xencor's stock was trading at $28.12 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, XNCR shares have increased by 13.2% and is now trading at $31.83.
View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Xencor?

11 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Xencor in the last year. There are currently 3 sell ratings, 1 hold rating and 7 buy ratings for the stock, resulting in a consensus recommendation of "Hold."
View analyst ratings for Xencor.

When is Xencor's next earnings date?

Xencor is scheduled to release its next quarterly earnings announcement on Tuesday, August 4th 2020.
View our earnings forecast for Xencor.

How were Xencor's earnings last quarter?

Xencor Inc (NASDAQ:XNCR) posted its earnings results on Thursday, May, 7th. The biopharmaceutical company reported ($0.14) earnings per share for the quarter, beating the Thomson Reuters' consensus estimate of ($0.42) by $0.28. The biopharmaceutical company had revenue of $32.39 million for the quarter, compared to analysts' expectations of $12.33 million. Xencor had a negative return on equity of 10.40% and a negative net margin of 79.39%.
View Xencor's earnings history.

What price target have analysts set for XNCR?

11 Wall Street analysts have issued 1-year price targets for Xencor's shares. Their forecasts range from $21.00 to $54.00. On average, they expect Xencor's stock price to reach $40.50 in the next twelve months. This suggests a possible upside of 27.2% from the stock's current price.
View analysts' price targets for Xencor.

What are Wall Street analysts saying about Xencor stock?

Here are some recent quotes from research analysts about Xencor stock:
  • 1. According to Zacks Investment Research, "Xencor Inc. is a clinical-stage biopharmaceutical company. It develops antibodies for the treatment of autoimmune diseases, asthma and allergic diseases, and cancer. Xencor Inc. is based in Monrovia, California. " (5/10/2020)
  • 2. Nomura Securities analysts commented, "‘18087 (SSTR2xCD3) 2H19 to 1H20, 0 Est ASCO as Expected. SSTR2 is a validated target in NET and GIST, but these are solid tumors and suffer from tumor microenvironment effects and potential on-target toxicities. ‘18087 (SSTR2xCD3) is now the only bispecific in XNCR’s platform that we currently value. NVS to Our View. Recall, the clinical hold lifted in April; dosing to resume in coming weeks, but “tunable potency” still in question. Last update on clinicaltrials.gov was May 2 and included a Aug 2019 study completion date – we anticipate with appropriate study completion, NVS will return rights. More p 3. Checks – XNCRs’s Bispec C max -Dependent with Redesign." (8/8/2019)

Has Xencor been receiving favorable news coverage?

Media coverage about XNCR stock has trended somewhat negative on Tuesday, according to InfoTrie Sentiment Analysis. The research group ranks the sentiment of press coverage by reviewing more than six thousand blog and news sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Xencor earned a news impact score of -1.7 on InfoTrie's scale. They also gave news headlines about the biopharmaceutical company a news buzz of 10.0 out of 10, indicating that recent press coverage is extremely likely to have an effect on the company's share price in the next few days.
View the latest news about Xencor.

Who are some of Xencor's key competitors?

Some companies that are related to Xencor include ACADIA Pharmaceuticals (ACAD), Bausch Health Companies (BHC), Jazz Pharmaceuticals (JAZZ), Emergent Biosolutions (EBS), Mirati Therapeutics (MRTX), United Therapeutics (UTHR), Reata Pharmaceuticals (RETA), Ultragenyx Pharmaceutical (RARE), Schrodinger (SDGR), Legend Biotech (LEGN), Zai Lab (ZLAB), Arrowhead Pharmaceuticals (ARWR), HYPERA S A/S (HYPMY), Myokardia (MYOK) and Evotec (EVTCY).
View all competitors.

What other stocks do shareholders of Xencor own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Xencor investors own include Intelsat (I), Bank of America (BAC), Cypress Semiconductor (CY), Apollo Global Management (APO), Intel (INTC), AbbVie (ABBV), Exelixis (EXEL), Fossil Group (FOSL), NVIDIA (NVDA) and Abercrombie & Fitch (ANF).

Who are Xencor's key executives?

Xencor's management team includes the following people:
  • Dr. Bassil I. Dahiyat Ph.D., Co-Founder, CEO, Pres & Director (Age 49)
  • Mr. John J. Kuch, Sr. VP of Fin., CFO & Sec. (Age 60)
  • Dr. John R. Desjarlais, Sr. VP of Research & Chief Scientific Officer (Age 55)
  • Dr. Paul A. Foster, Sr. VP & Chief Medical Officer (Age 65)
  • Mr. Charles Liles, Associate Director and Head of Corp. Communications & Investor Relations

What is Xencor's stock symbol?

Xencor trades on the NASDAQ under the ticker symbol "XNCR."

Who are Xencor's major shareholders?

Xencor's stock is owned by a number of retail and institutional investors. Top institutional investors include Candriam Luxembourg S.C.A. (0.81%), Rhenman & Partners Asset Management AB (0.46%), First Trust Advisors LP (0.11%), Comerica Bank (0.09%), Mackay Shields LLC (0.09%) and Vident Investment Advisory LLC (0.08%). Company insiders that own Xencor stock include Edgardo Baracchini, Jr, John J Kuch, John R Desjarlais, John S Stafford III, Paul A Foster and Ronin Capital, Llc.
View institutional ownership trends for Xencor.

Which institutional investors are selling Xencor stock?

XNCR stock was sold by a variety of institutional investors in the last quarter, including UBS Group AG, and Rhenman & Partners Asset Management AB. Company insiders that have sold Xencor company stock in the last year include John J Kuch, John R Desjarlais, John S Stafford III, and Ronin Capital, Llc.
View insider buying and selling activity for Xencor.

Which institutional investors are buying Xencor stock?

XNCR stock was purchased by a variety of institutional investors in the last quarter, including Candriam Luxembourg S.C.A., First Trust Advisors LP, Mackay Shields LLC, Diversified Trust Co, Vident Investment Advisory LLC, Vident Investment Advisory LLC, ProShare Advisors LLC, and Comerica Bank.
View insider buying and selling activity for Xencor.

How do I buy shares of Xencor?

Shares of XNCR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Xencor's stock price today?

One share of XNCR stock can currently be purchased for approximately $31.83.

How big of a company is Xencor?

Xencor has a market capitalization of $1.81 billion and generates $156.70 million in revenue each year. The biopharmaceutical company earns $26.88 million in net income (profit) each year or $0.46 on an earnings per share basis. Xencor employs 156 workers across the globe.

What is Xencor's official website?

The official website for Xencor is www.xencor.com.

How can I contact Xencor?

Xencor's mailing address is 111 WEST LEMON AVENUE, MONROVIA CA, 91016. The biopharmaceutical company can be reached via phone at 626-305-5900 or via email at [email protected]

This page was last updated on 8/4/2020 by MarketBeat.com Staff
Receive Analysts' Upgrades and Downgrades Daily

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.